Endoscopic ultrasound (EUS) allows visualization of celiac lymph nodes (CLNs) and celiac ganglia (CG). Reliably distinguishing these structures is important for tumor staging and CG ablative therapies. We aimed to evaluate the accuracy of EUS in distinguishing CLNs from CG using a strict cytopathology reference standard. We also determined the rate of detection of CLN and CG by conventional cross-sectional imaging.
E ndoscopic ultrasound (EUS) has become an essential tool for managing malignancies by improving diagnostic and staging accuracy, and guiding therapy. The capabilities of EUS have expanded to include the identification and biopsy of structures that are often radiographically occult and previously unrecognized at EUS, including peritoneal carcinomatosis, 1 diminutive hepatic metastasis, 2 malignant vascular thrombi, 3 extravascular migratory metastasis, 4 and celiac ganglia (CG) metastasis. 5 The accuracy of EUS imaging in identifying CG and distinguishing them from celiac lymph nodes (CLNs) has not been established. Likewise, the accuracy of computed tomography (CT) and magnetic resonance imaging (MRI) for detecting CG and distinguishing them from CLNs is uncertain. Accurate detection and distinction is clinically important to (1) allow therapeutic targeting of CG, [6] [7] [8] and may (2) enhance staging accuracy, (3) improve prognostic determination, and (4) guide overall therapy. Surgical and autopsy data demonstrate the impact of CG metastasis that some consider a marker for tumor upstaging and unresectability. EUS now allows preoperative confirmation CG status permitting future studies to verify the clinical impact and potential for inclusion in American Joint Committee on Cancer staging.
There is no existing reference standard to determine the test accuracy of EUS and cross-sectional imaging, as CG are rarely sampled at surgery or autopsy. Given that patients often have multiple CLNs and CG, cross-sectional imaging, surgery, and autopsy findings cannot ensure that the structure imaged at EUS was the same comparative structure examined by such reference standards. A true metric requires comparison to a cytologic reference standard that is obtained at the time of imaging. Our aim was to test the hypothesis that EUS imaging can accurately distinguish CG and CLNs using cytopathology as the reference standard.
Methods
The study was approved by the Institutional Review Board (15-008121). All patients provided written informed consent for the procedures and interventions performed. We retrospectively reviewed prospectively maintained EUS and cytopathology databases to identify all consecutive patients who underwent EUS fine needle aspiration (FNA) of a presumed CG or CLN from October 1, 2004 , to March 1, 2017 . Reporting is based on the Standards for Reporting of Diagnostic Accuracy recommendations with consideration of the overall value as a diagnostic test. 9 Endosonographers had access to all clinical data. Curvilinear echoendoscopy (Olympus GF-UC30P, GF-UC140P-AL5, GF-UCT180 or GF-UC160P-AT8; Olympus Medical Systems, Center Valley, PA; Pentax EG-3870UTK; Pentax Medical, Montvale, NJ) was performed. Specimens were collected using a standard 22-gauge FNA needle (Wilson-Cook Medical, Winston-Salem, NC) or 19-gauge Tru-cut device (Quick-Core, Wilson-Cook) or 22-gauge SharkCore FNB needle (Medtronic, Dublin, Ireland). Sites were biopsied only if a needle trajectory was found that avoided traversal of the primary tumor and other sites of possible metastasis. As per standard practice, the sampled structure was designated by the endosonographer as a CG, CLN, or an indeterminate celiac structure and each site was submitted separately for cytopathology review. EUS morphologic criteria used to designate the structure a CG or CLN was based on our prior work and experience (Figure 1A and B; Supplement 5). As opposed to CG, it has been our perception that the echodensity and Doppler signal substantially vary for CLNs, thereby prohibiting use of these features for evaluating CLNs. As this was a retrospective study, our group did not grade each of these individual criteria; rather, the EUS designation was based on the overall gestalt. In the same patient, with subtle torque of the echoendoscope, the edge of the same malignant celiac lymph node is seen (orange asterisk) as well as a malignant celiac ganglion (green asterisk) that were both cytologically proven.
What You Need to Know
Background Endoscopic ultrasound fine needle aspiration (EUS-FNA) allows visualization and sampling of celiac axis structures. Identification and differentiation of celiac lymph nodes from celiac ganglia is critical in clinical tumor staging and for celiac ganglia ablative therapies.
Findings EUS-FNA reliably identifies celiac lymph nodes and celiac ganglia with an overall accuracy of 94.7%.
Implications for patient care
Distinguishing celiac lymph nodes from celiac ganglia using EUS-FNA may begin to impact clinical tumor staging for in many patients with gastrointestinal malignancy as endosonographers become more experience with celiac axis EUS.
The endosonographic findings were compared with the final cytology interpretation conducted by a cytopathologist, the results of which provided the reference standard. As per standard practice, the cytopathologist had access clinical data and the index test. No other reference standards exist for comparison. Determination of CLN required the presence of a polymorphic population of lymphocytes without identifiable ganglion cells or nerve fibers (Figure 2 ). Determination of CG was based on the presence of nerve fibers or ganglion cells, without a significant lymphocyte population (Figure 3 ). When the official cytopathology report did not clearly specify these features, expert cytopathologists re-reviewed the cytopathology specimens. If the aspirated structure was unable to be defined after the re-review, it was deemed indeterminate. A subset of patients could not have a secondary review performed, due to lack of patient consent to have their pathology specimens used for research purposes.
One hundred randomly selected lesions in 94 patients with available high-quality CT or MRI films were reviewed by a dedicated gastroenterology radiologist to identify CLNs or CG. The composite CT or MRI results were used; therefore, detection of CLNs and CG by either modality was considered a positive test result. The radiologist was initially provided a test bank of 30 patients with the cytopathology results to facilitate his learning curve.
Methods of statistical analysis are detailed Supplement 6.
Results

Patient Characteristics
A total of 504 patients (age 63. 4 underwent EUS-FNA for a total of 566 lesions perceived to represent a CLN or CG (Figure 4 ). Fortyfive lesions had indeterminate cytology, based on the official cytology report, which could not be re-reviewed due to the lack of patient consent for research, leaving 521 lesions for which a cytologic confirmation was established. Cytologic proven CLNs and CG underwent a median of 3 (range, 1-13) vs 3 (range, 1-11) EUS-FNA passes, respectively. EUS was performed to evaluate a known or presumed malignancy in 81.3% of patients (Supplement 1). The most common underlying diagnosis was pancreatic adenocarcinoma followed by esophageal adenocarcinoma and cholangiocarcinoma (Supplement 3). Individual lesions varied from benign to malignant (Supplement 2).
Follow-Up and Adverse Events
Based on intraprocedural and postoperative recovery monitoring, clinical follow-up (conducted within 5 days in 429 [85.1%] patients), and chart review conducted within 30 days in all patients, 16 (3.2%) patients experienced an adverse event within 30 days of EUS (Supplement 7). None of these adverse events appeared to be related to the performance of CLN or CG FNA. Of the 16 patients who experienced an adverse event, 9 (56.3%) had undergone same-day endoscopic retrograde cholangiopancreatography.
Accuracy of EUS
The presumed site of FNA, as designated by the endosonographer, was categorized into 1 of 3 groups (Table 1, Figure 4 ).
Group 1: Presumed CLN based on EUS imaging. The endosonographer performed EUS-FNA of 332 lesions that were presumed to represent a CLN. Among this group, a cytological reference standard was available for 304 lesions, demonstrating that the site of FNA was a CLN, CG, or an indeterminate structure in 281 (92.4%), 5 (1.6%), and 18 (5.9%) lesions, respectively. When excluding the 18 lesions in which the cytological review was interpreted as indeterminate, the accuracy of EUS imaging for CLN detection was 98.3%.
Group 2: Presumed CG based on EUS imaging. The endosonographer performed EUS-FNA of 220 lesions presumed to represent a CG. Among this cohort, a cytological reference standard was available for 208 lesions, demonstrating that the site of FNA was a CG, CLN, or indeterminate structure in 166 (79.8%), 20 (9.6%), and 22 (10.6%) lesions, respectively. When excluding the 22 lesions in which the cytological review was interpreted as indeterminate, the accuracy of EUS imaging for CG detection was 89.2%.
Group 3: EUS imaging indeterminate whether lesion was a CLN or CG. The endosonographer performed EUS-FNA of an indeterminate structure 14 times. Among this group, a cytological reference standard was available for 9 lesions, demonstrating that the site of FNA was a CG, CLN, or indeterminate structure in 6 (66%), 0 (0%), and 3 (33%) lesions, respectively. When excluding lesions with indeterminate cytology, 6 of 6 (100%) of the lesions were CG.
Grouped Data
Excluding lesions that ultimately had indeterminate cytology, when EUS presumed a lesion to be CLN or CG the accuracy was 281 of 286 (98.3%) and 166 of 186 (89.2%), respectively, with an overall accuracy of 447 of 472 (94.7%). If one were to consider the 6 lesions that the endosonographer deemed indeterminate as representing an incorrect endosonographer interpretation, then the overall accuracy of EUS imaging was 447 of 478 (93.5%). A total of 478 lesions had definitive cytology of either CG or CLN following review. The test characteristics for EUS-FNA to correctly distinguish CG from CLN in this cohort was delineated, with the sensitivity, specificity, PPV and NPV being 93.3%, 93.7%, 96.2%, and 89.2%, respectively. For the 521 lesions with a cytologic reference standard, 43 (8.3%) specimens were cytologically interpreted as indeterminate for whether the lesion represented a CLN or CG. They included 18 of 304 (5.9%) EUS-presumed CLNs, 22 of 208 (10.6%) presumed CG, and 3 of 9 (33.3%) lesions deemed indeterminate at EUS (Supplement 4).
Factors Associated With Accuracy of EUS Imaging
A patient body mass index of 30-34.9 kg/m 2 was associated with an increased likelihood of EUS misidentifying a CG as a CLN (odds ratio, 9.62; 95% confidence interval, 1.37-67.36; P ¼ .026). Otherwise, age, gender, the date of EUS (evaluating earlier vs more recent experience), the endosonographer, overall diagnosis of a malignant process, and the presence of suspicious or malignant pathology in the aspirated lesions had no association with the accuracy of EUS imaging for distinguishing a CLN from a CG ( Table 2) .
Cross-Sectional Imaging Re-Review
For the randomly selected 100 re-reviewed lesions from 94 patients, 74 (78.7%) underwent CT only, 8 (8.5%) MRI only, and 12 (12.8%) underwent CT and MRI. The 100 cytology-confirmed lesions included 67 CLNs and 33 CG, among which 59 of 67 (88.1%) CLNs and 13 of 33 (39.4%) CG were identified, yielding an overall detection rate for CT or MRI of 72 of 100 (72.0%).
Discussion
The utility and role of EUS for cancer staging continues to grow, partly due to the discovery of once unappreciated sites of metastatic disease including the celiac ganglia. 5 To date the findings of CG metastasis has been restricted to surgical or autopsy specimens with data demonstrating a negative impact on patient outcomes. The ability to now identify and cytological verify CG metastasis will allow careful evaluation of the clinical impact and potential inclusion in staging systems. The identification of CG and CLNs is also important as CG may be targeted for pain management. [6] [7] [8] However, when CG are injected with steroids or ethanol, or radiofrequency ablation is delivered, the injectate and energy can dissipate through FNA puncture sites, thereby limiting the intraganglionic therapy and potentially heightening the risk. Accurate identification of CG may obviate the need for initial FNA and avoid separate diagnostic and subsequent therapeutic exams.
While the visualization of CG at EUS has been previously described using specified sonographic criteria, [10] [11] [12] objective quantification of its accuracy in identifying and distinguishing CLNs and CG using confirmatory cytopathology has not been explored. We previously reported that CG could be identified at EUS in 162 of 200 (81%) patients, with detection rates varying among 4 endosonographers from 65% to 97% (P ¼ .007). 11 However, the strength of that conclusion was limited by the lack of a comparative cytological reference standard. In addition, our prior study was not designed to determine the ability to distinguish CG from CLNs.
In this study, endosonographers were more accurate when they believed that they had sampled a CLN (98.3%) vs a presumed CG (89.2%). The greater difficulty in identifying CG is further suggested by the fact that when the endosonographer was uncertain as to the site of FNA, the cytology reference standard demonstrated a CG in 66%, a CLN in 0%, and an indeterminate lesion in 33% of patients. Although is it not clear why EUS was superior in identifying CLNs, one possible explanation is that an increased proportion of lesions with indeterminate cytology were actually CG that could not be proven due to inadequate sampling. This assumption is supported by the finding of indeterminate cytology in 10.6% vs 5.9% of the patients with presumed CG versus CLN, respectively. Such information may be helpful for endosonographers in deciding the role of FNA in their practice and the potential need for a greater number of FNAs when sampling presumed CG to achieve specimen adequacy.
As CLNs and CG are located in close proximity, one might question why CG had not been detected until recently, and whether in fact endosonographers were occasionally inadvertently sampling CG instead of presumed CLNs. This issue was addressed by ElGabry et al, 13 who evaluated how often they inadvertently performed FNA of a CG. In a cohort of 354 patients who underwent EUS-FNA of a presumed CLN (n ¼ 334) or celiac mass (n ¼ 20), they found that 9 (2.5%) lesions instead represented CG. We believe several factors may account for the delayed detection of CG. First, when the biopsy site is presumed to be a CG, it can be difficult to obtain neural glial cells. We have subjectively recognized that a greater degree of negative pressure and an increased number of forceful staccato to-and-fro needle motions are needed to obtain neural glial cells. Second, given the irregular and heterogeneous appearance of CG, we believe they may be masked by surrounding tissues. Finally, while it is our standard of practice for cytopathologists to report the presence or absence of ganglion cells and nerve fibers within their official report, this is likely not the situation in most centers. There are limited data regarding the identification and differentiation of CLN and CG using cross-sectional imaging and none compared with a pathologic reference standard other than cadaveric correlation, [14] [15] [16] and no prior studies comparing cross-sectional imaging to EUS. In a study of 103 patients, multidetector CT identified CG in 89% of patients, using cadaveric dissection with gross visualization of CG as the reference standard. 15 CG may also be identified using MRI as shown in another study that also relied on cadaveric dissection with gross visualization as the reference standard. 16 However, the latter study did not evaluate accuracy. Our study was strengthened by the evaluation of a large number CG and CLNs with comparison to a cytological reference standard. We also have the experience of a large number of endosonographers, which aids in terms of the applicability of our findings. A study limitation was its retrospective design. As a result, the procedures were not protocoled in terms of the EUS-FNA technique and CG and CLN features were often incompletely documented, prohibiting correlation of morphologic features with accuracy. The study does not allow equal comparison of CT or MRI to EUS-FNA, given that inclusion was based on EUS detection. Finally, one cannot be sure that the particular CLN or CG that underwent FNA was the same structure seen on cross-sectional imaging. This is problematic as patients have multiple CG and CLNs and one cannot ensure that the radiologist and endosonographer described the same lesion.
We were surprised to discover that 43 of 521 (8.3%) FNA specimens were cytologically indeterminate for a CLN or CG even after dedicated re-review. This might suggest that we performed an insufficient number of needle passes or used inadequate technique in some patients. The absence of lymphocytes (n ¼ 8) and ganglion cells (n ¼ 6) for EUS-presumed CLNs and CG, respectively, suggests that the endosonographer misidentified these 14 lesions. There is uncertainty whether the endosonographer correctly identified the 29 lesions deemed cytologically indeterminate because of inadequate sampling (n ¼ 4) or the presence of abundant malignant cells and absence of lymphocytes or ganglion cells (n ¼ 25). In most of these cases, the cytologist cited an inability to identify normal cellular components due to the replacement by malignant cells and necrotic debris. Limitations in endosonographer performance may be amplified by the uncertainty of cytotechnologists during on-site review when a structure has been infiltrated by cancer cells. Our results call for greater education of both endosonographers and cytotechnologists within our group and likely among other institutions as well. We anticipate that detection or exclusion of neural elements can be performed only after complete sample preparation, appropriate slide staining and upon final cytopathology review. Work is needed to determine the accuracy of rapid onsite evaluation.
Defining the accuracy of EUS in identifying and distinguishing celiac structures is critical in refining diagnostic and therapeutic applications moving forward. We demonstrated the feasibility and accuracy of EUS for distinguishing CLNs and CG across a group of endosonographers. The results impact cancer staging that is closely linked to treatment options and outcomes. Accurate localization also helps guide CG interventions. Additional work is needed to demonstrate the effect on clinical decision making and patient outcomes. Similar studies are required for cross-sectional imaging. Thereafter, we anticipate that cross-sectional imaging and EUS will provide complementary diagnostic and staging information. Until then, we regard EUS as the current reference standard.
Finally, while limited autopsy data indicate that CG metastasis correlates with poor prognosis and shortened survival, [17] [18] [19] the American Joint Committee on Cancer does not include this site of metastasis in their staging algorithm. 20 The omission may result from the prior inability to preoperatively detect and biopsy CG. Our study findings can facilitate prospective trials aimed to evaluate the risk of CG cancer metastasis and the resulting impact on cancer staging, prognosis, therapy, and outcomes.
Conclusions
The role and utility of EUS as a diagnostic and therapeutic modality continues to evolve. Our data indicate that EUS accurately distinguishes CLNs from CG when compared with a cytologic reference standard. These findings further support the use of EUS for enhancing clinical tumor staging accuracy, for administering stage appropriate therapy, and to help to guide the development of new clinical and therapeutic celiac ganglia applications. The study data should facilitate future trials aimed at detecting CG metastasis and for determining the resulting impact on cancer staging, prognosis, therapy, and outcomes. Additional work is needed to decrease the rate of indeterminate cytology when sampling celiac ganglia.
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Supplement 5. Endoscopic Ultrasound Features of Celiac Ganglia and Celiac Lymph Node
Based on our initial work and experience identifying and sampling celiac ganglia (CG), our group has considered the following endoscopic ultrasound (EUS) morphologic features to be indicative of CG ( Figure 1A 
Supplement 6. Methods of Statistical Analysis
A sample size calculation was not performed for this retrospective study as there is presently no other established reference standard. Instead, the data from all consecutive patients were included, beginning at the date of first performing EUS fine needle aspiration (FNA) of a presumed CG. The EUS imaging (i.e. index test) results were compared to the cytology result (i.e. reference standard). Descriptive statistics are reported as frequency (%) for discrete variables and as mean AE SD for continuous variables. The performance characteristics were determined after excluding patients with indeterminate cytology for whom a reference standard was not available. The performance characteristics were also recalculated after considering the 6 lesions that the endosonographer deemed indeterminate as representing an incorrect endosonographer interpretation. Univariate logistic regression was used to assess variable associations with an incorrect EUS diagnosis, which was performed for the entire cohort and separately for CLN cytology and CG cytology. Odds ratio with 95% confidence interval (CI) was reported. All tests were 2 sided with the alpha level set at <0.05. Analyses were done using SAS version 9.4 software (SAS Institute, Cary, NC) and JMP Version 10 (SAS Institute Inc). For the 45 of 566 lesions that could not be re-reviewed, due to the lack of patient consent for research the data were excluded from analysis.
Supplement 7. Adverse Events
Adverse events included: mild transient abdominal pain (n ¼ 7), mild GI bleeding (n ¼ 2), death from unknown cause 3 days later (n ¼ 1), non-ST-segment elevation myocardial infarction (n ¼ 1), duodenal perforation (n ¼ 1), mild pancreatitis (n ¼ 1), dental fracture (n ¼ 1), fever (n ¼ 1), and moderate sedation resulting in respiratory suppression and extended observation without need for intervention (n ¼ 1). 
